{
    "Trade/Device Name(s)": [
        "LIAISON\u00ae Anti-HAV",
        "LIAISON\u00ae Control Anti-HAV"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K082049",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LOL",
        "JJX"
    ],
    "Summary Letter Date": "December 5, 2008",
    "Summary Letter Received Date": "October 27, 2008",
    "Submission Date": "October 24, 2008",
    "Regulation Number(s)": [
        "21 CFR 866.3310"
    ],
    "Regulation Name(s)": [
        "Hepatitis A Virus Serological Reagents"
    ],
    "Analyte Class(es)": [
        "virology",
        "serology"
    ],
    "Analyte(s)": [
        "Total anti-HAV antibodies"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Sodium heparinized plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "LIAISON\u00ae Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)"
    ],
    "Methodologies": [
        "Competitive sandwich CLIA",
        "Neutralization immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for LIAISON\u00ae Anti-HAV qualitative chemiluminescent immunoassay for detection of antibodies to hepatitis A using the LIAISON\u00ae Analyzer",
    "Indications for Use Summary": "Qualitative detection of total antibodies to hepatitis A in human serum and sodium heparinized plasma as an aid in the laboratory diagnosis of current or previous HAV infections and determination of antibody response to HAV in vaccine recipients; controls for assay performance monitoring",
    "fda_folder": "Microbiology"
}